Navigation Links
Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Date:11/28/2012

GREENWOOD VILLAGE, Colo., Nov. 28, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced the appointment of Josh Disbrow as Chief Operating Officer of Ampio Pharmaceuticals, effective December 15, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

Mr. Disbrow was most recently the Vice President of Commercial Operations at Arbor Pharmaceuticals. He joined Arbor in 2007 as the company's second full time employee and led the company's commercial efforts from inception to $127 million in annual sales in 2011 at which time the company was sold to an investor group. Since the company's acquisition, Josh remained with Arbor and oversaw the growth of the company's commercial infrastructure to over 150 people in sales, marketing, and other commercial functions. During his time at Arbor, Josh also served as the company's commercial lead on all business and corporate development activities including in-licensing, out-licensing, partnering, mergers and acquisitions, and university collaborations.

Arbor began as an entrepreneurial venture with no products on the market. Through Josh's leadership Arbor developed into a fully integrated specialty pharmaceutical company with a focus on bringing novel prescription pharmaceuticals to market through efficient product development, aggressive business development, corporate partnerships, and efficient commercial scale-up.

Mr. Disbrow has spent 17 years in the pharmaceutical, diagnostic, and medical device industries and has held positions of increasing responsibility in sales, marketing, sales management, commercial operations, and commercial strategy.
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
2. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
3. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
7. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
10. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ ... clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and ... third quarter 2014 financial results on Thursday, November ... team will host a live conference call and ... financial results and provide a business update. ...
(Date:10/30/2014)... Chicago, Illinois (PRWEB) October 30, 2014 ... Regenerative and Cellular Medicine Showcase in Chicago, leading ... and Orthopedic Surgeon, Dr. Wade McKenna presented talks ... Effectiveness and Orthopedic Surgical Applications For Stem Cells. ... of amniotic membrane and the properties of AlphaGEMS ...
(Date:10/30/2014)... James Sherley says he has been working towards ... technology since his days as a principal investigator at the ... 1990’s. Sherley founded the ASCTC as a new Boston ... intellectual property developed in Sherley’s research over the years since ... Technology (MIT), and more recently as a senior scientist at ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success ... of its fleet of high volume High Pressure Processing (HPP) ... we return to PackExpo this year, which is where we ... said Jeff Williams, CEO at Avure. “Sales of the new ... be meeting the challenges of market demand for higher throughput. ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... , ,Green Bay, Wis. MailFoundry , maker ... new high availability MailFoundry anti-spam appliances, the MailFoundry ... and $12,999, respectively, with no user, domain or ... appliances are powered by Solinus' MessageIQ email scanning ...
... places to grow new businesses, according to a national magazine. , ... while Madison is sixth among mid-sized cities. , ,The trio ... 20 th . , ,The rankings are published in October's issue ... was on the list in 1999, according to Gov. Jim Doyle, ...
... are ahead for IT businesses, according to market research firm ... will have found their key roles transformed. Ten percent will ... themselves relegated to commodity status. , ,The predictions were made ... , ,The changes are being driven by maturing IT ...
Cached Biology Technology:Tech Digest: MailFoundry; API Software 2Radical changes predicted for IT groups 2
(Date:10/29/2014)... ceremony held in New York City on September 19, ... American Cancer Society Professor of Genome Sciences and Medicine ... Honorary Doctor of Philosophy of Tel Aviv University, was ... Science. , In addition to her honorary degree from ... the TAU School of Medicine, and for the past ...
(Date:10/29/2014)... kind of stem cell, those referred to as ,facultative, ... is apparently nothing that differentiates these cells from the ... they retain the capacity to become stem cells again. ... an organ that hosts cells that stimulate tissue growth, ... case of a transplant. Knowledge of the underlying ...
(Date:10/29/2014)... the living world compete with members of their ... much they invest into their competitive ability. Some ... access to high-quality resources, while others seem to ... lower-quality resources that are left over for them. ... human societies seems to fluctuate considerably over time. ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... (CRF) brings experts to New York City from ... Conference on Cell Therapy for Cardiovascular Diseases. Dedicated ... three-day session will feature an in-depth review of ... and cutting-edge research findings. Highlights include: ...
... facilitate the remarkably fast adaptation of intestinal bacteria within ... of PLoS Genetics by researchers from INSERM and INRA ... a simplified but ecologically relevant system the authors ... Escherichia coli MG1655. E. coli is naturally resident within ...
... In the latest issue of the journal Emerging ... in the hyperboreal tundra, in connection with the ... bacteria. These findings indicate that resistance to ... alarming prospect for future health care. The ...
Cached Biology News:Cell Therapy for Cardiovascular Diseases 2Cell Therapy for Cardiovascular Diseases 3Dissecting the genetic components of adaptation of E. coli to the mouse gut 2High degree of resistance to antibiotics in Arctic birds 2
... for maximum packaging efficiencies of T7Select vectors ... (> 109 pfu/g with control DNA) make ... at least 5 107 recombinant plaques ... from a specially designed phage that reduces ...
... delivers enhanced statistics and statistical interpretation ... improvement managers. As an accepted organizational ... simplifies statistics for novice users and ... experts. It offers a powerful JMP ...
... Mouse anti-Yersinia pestis F1 antigen, Monoclonal ... ELISA: Use at an ... an assay dependent dilution. WB: Use ... molecular weight: 18 kDa. Not tested ...
...
Biology Products: